Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma
Despite initial high response rates of low grade Non Hodgkin lymphoma, progressive or
refractory disease currently remains incurable. Being a radiosensitive tumor, we hypothesize
that combining different modalities of treatment including targeted radioimmunotherapy
(RIT), and a graft versus lymphoma effect related to an allogeneic non myeloablative stem
cell transplant may increase response and survival rates in a safe manner in patients with
persistent disease following initial treatment. In this study patients who are not eligible
for a standard stem cell transplant approach because of relapsed or refractory disease and
who have a related sibling donor are treated with RIT followed by an allogeneic non
myeloablative blood stem cell transplant
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD
one year
Yes
Thomas Kiss, MD
Principal Investigator
Maisonneuve-Rosemont Hospital
Canada: Health Canada
ZEV0701
NCT00807196
September 2008
December 2012
Name | Location |
---|